Abstract Background Staphylococci represent the first etiologic agents of bone and joint infection (BJI), leading glycopeptides use, especially in case of methicillin-resistance or betalactam intolerance. Teicoplanin may represent an alternative to vancomycin because of its acceptable bone penetration and possible subcutaneous administration. Methods Adults receiving teicoplanin for S. aureus BJI were included in a retrospective cohort study investigating intravenous or subcutaneous teicoplanin safety and pharmacokinetics. Results Sixty-five S. aureus BJIs (orthopedic device-related infections, 69 %; methicillin-resistance, 17 %) were treated by teicoplanin at the initial dose of 5.7 mg/kg/day (IQR, 4.7–6.5) after a loading dose of 5 inject...
Introduction: Today, orthopedic prostheses are being increasingly utilized in people with degenerati...
Fifty-four patients with chronic osteomyelitis sustained by methicillin-resistant staphylococcus wer...
ABSTRACf: Teicoplanin is a new glycopeptideantibiotic with potent activityagainst gram-positivebacte...
Background: Staphylococci represent the first etiologic agents of bone and joint infection (BJI), le...
Staphylococci represent the first etiologic agents of bone and joint infection (BJI), leading glycop...
Context: Subcutaneous administration of antibiotic therapy is routinely practiced by 95% of infectio...
Oxacillin-resistant staphylococci are the most serious pathogens in chronic osteomyelitis and only g...
Teicoplanin, 200-400 mg (3-6 mg/kg) daily iv or im, was used to treat 71 episodes of infection. The ...
The prophylactic and therapeutic activities of teicoplanin were evaluated in two different experimen...
Treatment of difficult-to-treat infections such as osteomyelitis or infections related to indwelling...
Treatment of difficult-to-treat infections such as osteomyelitis or infections related to indwelling...
Brusseb, Belgium Twenty-one patients were included in an open randomized study comparing vancomycin ...
WOS: 000254066100008PubMed: 18343744We evaluated the efficacy of tigecycline and teicoplanin in a ra...
Teicoplanin, a glycopeptide antibiotic for methicillin-resistant Staphylococcus aureus, is recommend...
Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is increasing. V...
Introduction: Today, orthopedic prostheses are being increasingly utilized in people with degenerati...
Fifty-four patients with chronic osteomyelitis sustained by methicillin-resistant staphylococcus wer...
ABSTRACf: Teicoplanin is a new glycopeptideantibiotic with potent activityagainst gram-positivebacte...
Background: Staphylococci represent the first etiologic agents of bone and joint infection (BJI), le...
Staphylococci represent the first etiologic agents of bone and joint infection (BJI), leading glycop...
Context: Subcutaneous administration of antibiotic therapy is routinely practiced by 95% of infectio...
Oxacillin-resistant staphylococci are the most serious pathogens in chronic osteomyelitis and only g...
Teicoplanin, 200-400 mg (3-6 mg/kg) daily iv or im, was used to treat 71 episodes of infection. The ...
The prophylactic and therapeutic activities of teicoplanin were evaluated in two different experimen...
Treatment of difficult-to-treat infections such as osteomyelitis or infections related to indwelling...
Treatment of difficult-to-treat infections such as osteomyelitis or infections related to indwelling...
Brusseb, Belgium Twenty-one patients were included in an open randomized study comparing vancomycin ...
WOS: 000254066100008PubMed: 18343744We evaluated the efficacy of tigecycline and teicoplanin in a ra...
Teicoplanin, a glycopeptide antibiotic for methicillin-resistant Staphylococcus aureus, is recommend...
Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is increasing. V...
Introduction: Today, orthopedic prostheses are being increasingly utilized in people with degenerati...
Fifty-four patients with chronic osteomyelitis sustained by methicillin-resistant staphylococcus wer...
ABSTRACf: Teicoplanin is a new glycopeptideantibiotic with potent activityagainst gram-positivebacte...